APC Anti-TMEM175 antibody [EPR24415-47],Abcam,AB318503
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
Host
Rabbit
Reactivity
Human
Application
Target Binding Affinity, IHC-P, Antibody Labelling
Conjugate
APC
Platform ID
BAB274823637
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Proton-activated proton channel that catalyzes proton efflux from endosomes and lysosomes to maintain a steady-state pH (PubMed : 35333573, PubMed : 35750034, PubMed : 37390818). Activated at low pH (under pH 4.6) by luminal side protons : selectively mediates lysosomal proton release from lysosomes, eliciting a proton leak that balances V-ATPase activity to maintain pH homeostasis (PubMed : 35750034). Regulation of lumenal pH stability is required for autophagosome-lysosome fusion (PubMed : 26317472, PubMed : 32267231). Also acts as a potassium channel at higher pH, regulating potassium conductance in endosomes and lysosomes (PubMed : 26317472, PubMed : 28723891, PubMed : 32228865, PubMed : 32267231, PubMed : 33505021). Constitutes the pore-forming subunit of the lysoK(GF) complex, a complex activated by extracellular growth factors (PubMed : 33505021). The lysoK(GF) complex is composed of TMEM175 and AKT (AKT1, AKT2 or AKT3), a major target of growth factor receptors : in the complex, TMEM175 channel is opened by conformational changes by AKT, leading to its activation (PubMed : 33505021). The lysoK(GF) complex is required to protect neurons against stress-induced damage (PubMed : 33505021). See full target information TMEM175
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.